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Abstract 
The main challenge in treating opioid addicts is to maintain abstinence due to the affective 
consequences associated with withdrawal which may trigger relapse. Emerging evidence 
suggests a role of the neurohypophysial peptide oxytocin in the modulation of mood 
disorders as well as drug addiction. However, its involvement in the emotional consequences 
of drug abstinence remains unclear. We investigated the effect of 7-day opioid abstinence on 
the oxytocinergic system and assessed the effect of the oxytocin analogue carbetocin on the 
emotional consequences of opioid abstinence, as well as relapse. Male C57BL6J mice were 
treated with a chronic escalating-dose morphine regimen (20-100 mg/kg/day, i.p.). Seven 
days withdrawal from this administration paradigm induced a decrease of hypothalamic 
oxytocin levels and a concomitant increase of oxytocin receptor binding in the lateral septum 
and amygdala. While no physical withdrawal symptoms or alterations in plasma 
corticosterone levels were observed after seven days of abstinence, mice exhibited increased 
anxiety-like and depressive-like behaviors and impaired sociability. Carbetocin (6.4 mg/kg, 
i.p.) attenuated the observed negative emotional consequences of opioid withdrawal. 
Furthermore, in the conditioned place preference paradigm with 10 mg/kg morphine 
conditioning, carbetocin (6.4 mg/kg, i.p.) was able to prevent the stress-induced reinstatement 
to morphine-seeking following extinction. Overall, our results suggest that alterations of the 
oxytocinergic system contribute to the mechanisms underlying anxiety, depression and social 
deficits observed during opioid abstinence. This study also highlights the oxytocinergic 
system as a target for developing pharmacotherapy for the treatment of emotional impairment 
associated with abstinence and thereby prevention of relapse. 
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Introduction 
Opioid addiction is a chronic relapsing disorder characterized by the emergence of negative 
physical and emotional withdrawal symptoms, which serve as a motivational trigger to re-
administer the drug and to relapse (Le Moal and Koob, 2007). The major challenge for opioid 
addicts who are recovering from their addiction is the maintenance of a drug-free state. 
Physical symptoms of withdrawal decrease after a short period of time, but symptoms 
associated with emotional distress and dysphoria such as anxiety, irritability, stress, 
depression and anhedonia may persist for several months (Jaffe, 1990; Martin and Jasinski, 
1969; Nunes et al, 2004; Peles et al, 2007). Moreover, the adverse social consequences of 
opioid withdrawal in recovering addicts are well recognized and benefits of psychosocial 
support in maintaining abstinence have been reported (Veilleux et al, 2010). 
Although some neurotransmitter systems (e.g., serotonin and corticotropin-releasing factor) 
have been suggested to be involved (Goeldner et al, 2011; Koob and Kreek, 2007; Koob, 
2008), the mechanisms underlying the emotional impairment associated with opioid 
abstinence remain largely unclear. Several lines of evidence suggest a role of the “social” 
peptide oxytocin (OT) in drug addiction. OT-producing neurons located in the hypothalamus 
innervate brain regions associated with drug-seeking behavior as well as stress, mood, fear 
and emotionality, such as the amygdala, septum and the bed nucleus of stria terminalis, where 
oxytocin receptors (OTRs) are expressed (Gimpl and Fahrenholz, 2001). OT is involved in 
the regulation of stress via its action on the hypothalamo-pituitary-adrenal (HPA) axis 
(Windle et al, 2004), and has been also implicated in the modulation of emotional and social 
behaviors (Neumann and Landgraf, 2012). In particular, OT promotes social bonding as well 
as social memory (Keverne and Curley, 2004) and exerts a potent anxiolytic, anti-aggressive 
and antidepressant effect in humans (Heinrichs and Domes, 2008; Liu et al, 2012), and in 
animal models (Neumann et al, 2012).  
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There is emerging evidence supporting the involvement of OT in the effects of a number of 
drugs of abuse and in preventing relapse to drug-seeking (Broadbear et al, 2011; McGregor 
and Bowen, 2012; McGregor et al, 2008; Sarnyai, 2011). With respect to opioids, an 
inhibitory effect of OT has been demonstrated on morphine tolerance, physical symptoms of 
naloxone-precipitated morphine withdrawal (Kovacs et al, 1985; Kovacs et al, 1984) and on 
heroin self-administration (Kovacs and Van Ree, 1985) in rodents. In addition, marked 
alterations in OT peptide content and/or synthesis were reported in the forebrain, 
hippocampus, amygdala and hypothalamus of rodents following acute and chronic opioid 
administration (Kovacs et al, 1987; You et al, 2000). With respect to relapse, OT was shown 
to facilitate extinction of methamphetamine-induced conditioned place preference (CPP) and 
to attenuate stress- (Qi et al, 2009) and priming- (Carson et al, 2010) induced reinstatement 
of methamphetamine-seeking behavior in rodents. Overall, while the contribution of OT in 
different stages of drug addiction is recognized, its specific role in the emotional impairment 
associated with abstinence, which may trigger relapse to drug-seeking, remains largely 
unknown. 
Our aim was to assess whether OT alterations may underlie negative emotional states 
associated with opioid abstinence. Specifically, we hypothesize that 7-day withdrawal from 
chronic morphine administration, causes alterations of the central OT-ergic system and that 
an OT analogue may attenuate the emotional consequences of 7-day opioid abstinence and 
prevent relapse. We used a mouse model of 7-day, morphine abstinence to study the effects 
of withdrawal on OT peptide levels and OTR binding in the brain. The emergence of 
emotional impairment (i.e., anxiety, depressive-like behaviors and sociability deficits) was 
also assessed following this 7-day withdrawal period. We then examined the effect of the OT 
analogue carbetocin (CBT) on the negative emotional consequences of withdrawal, as well as 
the stress-induced reinstatement of morphine-seeking behavior. 
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Materials and Methods 
Animals and paradigm for morphine administration and withdrawal 
Male C57BL/6J mice (seven-week old, 20-25 g, Charles River Laboratories, Kingston, UK), 
were housed individually in a temperature-controlled environment with a 12:12-hour 
light/dark cycle (lights on: 06:00).  Food and water were available ad libitum. Mice were left 
to acclimatize in their new environment for seven days prior to the experiments and were 
handled daily. All procedures received a favorable opinion by the University of Surrey Ethics 
Committee and were approved by the UK Home Office (Animals Act 1986). Mice were 
randomly assigned to two treatment groups: control saline-treated groups (n=148 in total) and 
chronic morphine-treated groups (n=161 in total). Mice were injected (i.p.) either with saline 
(4 ml/kg) or morphine (Sigma-Aldrich, Poole, UK) with a chronic morphine escalating-dose 
administration paradigm (20 mg/kg on day 1, 40 mg/kg on days 2-3, 80 mg/kg on days 4-5 
and 100 mg/kg on days 6-7), twice per day at 09:00 and 17:00, as previously described 
(Goeldner et al, 2011; Muller and Unterwald, 2004; Zhou et al, 2006), with minor 
modifications (Fig. S1A). To induce withdrawal, mice were then left in their home cage for 7 
consecutive days without receiving any injection, which was previously shown to induce 
characteristic enhancement of depressive-like behavior in rats (Anraku et al, 2001). 
Effect of chronic morphine treatment and 7-day abstinence on the central oxytocinergic 
system and plasma corticosterone levels  
Mice were killed by decapitation either 1 hour after the final treatment injection for the 
chronic morphine and saline groups, or after 7 days of withdrawal. Brains were frozen in 
isopentane solution  (-20oC) and sectioned for analysis of autoradiographic OTR binding 
(n=5 per group) as previously described (Zanos et al, 2013). Alternatively, brain regions were 
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dissected (i.e., hypothalamus, septum, amygdala, hippocampus; n=6-7 brains per group) for 
determining OT peptide levels. Peptide extraction was performed  according to Szeto et al, 
(2011), using a previously described protocol with minor modifications (Christensson-
Nylander et al, 1985). Measurement of OT levels was performed on tissue extracts using an 
Enzyme Immunoassay (Enzo Life Sciences (UK) Ldt, Exeter, UK). Trunk blood was also 
collected for quantification of plasma corticosterone levels (n=11-12 per group) using a 
commercially available radioimmunoassay kit, according to manufacturer’s instructions (MP 
biochemical, New York, NY, USA). 
Effect of morphine administration and abstinence on physical symptoms of withdrawal 
in mice 
Basal locomotor activity, number of withdrawal jumps, fecal boli, body weight, food and 
water intake were recorded daily, at the same time, throughout the chronic morphine 
administration paradigm and/or at specific time points during the withdrawal period (n=13-18 
mice per group; Supplementary Methods).  
Effect of morphine abstinence and carbetocin administration on anxiety-, depressive-
like and sociability behaviors 
A different cohort of mice underwent chronic morphine administration, as described above.  
Following a 7-day withdrawal period, mice were injected (i.p.) either with saline (4 ml/kg) or 
CBT (6.4 mg/kg), 15 min prior to measuring anxiety- and depressive-like behavior using the 
elevated plus-maze and forced-swim tests, or 5 min prior to the assessment of sociability and 
social novelty behavior using the Crawley’s three-chambered social approach test (for details, 
see Supplementary Methods). Each behavioral test was performed on a separate group of 
animals (n=7-10 per group). The dose was chosen based on previous studies (Chaviaras et al, 
2010) and a pilot experiment assessing the effects of CBT (i.p.; Vehicle n=6; 2 mg/kg, n=3; 
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6.4 mg/kg, n=10, and 20 mg/kg, n=3) on depressive-like behavior in mice withdrawn for 7 
days from chronic saline or morphine administration, using the forced-swim test 
(Supplementary Methods and Fig. S2). While CBT did not induce any alterations of 
parameters characteristic of depressive-like behavior in the saline-withdrawn group, this 
compound dose-dependently reduced the depressive-like symptoms observed in the 
morphine-withdrawn mice. We selected the lowest dose able to reverse depressive-like 
behavior in morphine-abstinent mice, i.e., 6.4 mg/kg. This dose did not have any significant 
effect on locomotor activity in naïve mice (n=6 per group; data not shown). CBT was 
selected because of its half-life (85-100 min) compared to OT (3-5 min) and based on its 
selectivity to the OTR in the rat (Engstrom et al, 1998). 
Effect of carbetocin administration on stress-induced reinstatement of morphine-
seeking behavior 
We used a CPP apparatus (Opto-Max Activity Meter v2.16, Columbus Instruments, OH, 
USA), as previously described (Bailey et al, 2010). The CPP reinstatement protocol was 
modified from (Mantsch et al, 2010). Briefly, it consisted of a habituation session, pre-
conditioning test, 4 conditioning sessions (morning saline  and 4 hours later a 10 mg/kg 
morphine subcutaneous (s.c.) injections daily), a post-conditioning test, 5 extinction sessions 
(i.e., morphine injection was replaced by a saline injection), a post-extinction test and a 
reinstatement session, each carried out on consecutive days (Fig. 5A). During the 
reinstatement session, mice were pre-treated with either saline (4 ml/kg, i.p.; n=14 mice) or 
CBT (6.4 mg/kg, i.p.; n=12 mice) and after 5 minutes, they were exposed to a 6-min forced-
swim session.  Following the forced-swim stress, mice were towel-dried and placed in the 
CPP apparatus for 20 minutes. Time spent in each compartment was measured during the last 
15 minutes of the session. Mice were killed 30 minutes after the reinstatement session and 
trunk blood was collected for quantification of plasma corticosterone levels. 
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To ascertain that CBT does not have any rewarding or aversive effects on its own when 
administered chronically, the effects of CBT (6.4 mg/kg, i.p.) were compared to saline in a 
CPP paradigm, consisting of one  habituation, one pre-conditioning, four conditioning (with 
saline injection in the morning and CBT administration 4 hours later) phases and one post-
conditioning phase. Time spent in each compartment was assessed during the last 15 minutes 
of the 20-min post-conditioning session and compared in the CBT- and saline-treated groups 
(n=6 per group). 
Statistical Analyses 
All the values were expressed as mean ± SEM. For analyses of OTR binding, OT peptide and 
corticosterone levels, two-way ANOVA with factors ‘treatment’ (i.e., saline or morphine) 
and ‘7-day withdrawal’ was performed. The effects of CBT on the elevated plus-maze, 
forced-swim test and sociability tests were compared by two-way ANOVA with factors 
‘treatment’ (i.e., saline or morphine) and ‘CBT’ (i.e., CBT or saline). Differences in stress-
induced reinstatement of morphine-seeking were analyzed using two-way ANOVA with 
factor ‘CPP phase’ (pre-conditioning, post-conditioning, post-extinction, reinstatement) and 
‘experiment’ (i.e., CBT or saline). The effects of CBT on CPP and locomotor activity were 
assessed by repeated measures two-way ANOVA with factors ‘CPP phase’ and ‘CBT’ (i.e., 
CBT or saline), and factors ‘time’ and ‘CBT’ (i.e., CBT or saline) respectively. Differences 
in weight changes, food and water intake were assessed by two-way repeated measures 
ANOVA with factors ‘treatment’ (i.e., saline or morphine) and ‘days’. Basal locomotor 
activity was analysed by repeated measures two-way ANOVA with factors ‘treatment’ (i.e., 
saline and morphine) and ‘days’. ANOVAs were followed by a Holm-Sidak post-hoc test 
when significance was reached (i.e. p<0.05). All relevant F-values are provided in Table 1. 
All statistical analyses were performed using SigmaPlot (Systat Software Inc, London, UK).   
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Results 
Effect of chronic morphine administration and 7-day withdrawal on the central 
oxytocinergic system and plasma corticosterone levels 
We first investigated the effects of chronic, escalating-dose morphine administration and 7-
day withdrawal on OTR binding in the brain (Fig. 1A-B; Table 1). A significant effect of the 
7-day morphine treatment was observed in several brain regions (Table 1). The morphine-
treated groups showed an increase in OTR binding in the piriform cortex, medial septum, 
vertical limb of the diagonal band of Broca, as well as the anterior olfactory nucleus-ventral 
and -lateral, compared to the control saline-treated groups (Table 1). In the lateral septum and 
amygdala, a significant ‘treatment’ x ‘withdrawal’ interaction was identified (Table 1). While 
chronic morphine administration did not alter the OTR binding in the lateral septum, we 
observed a significant increase in the 7-day morphine-withdrawn group compared to the 
saline-withdrawn group and to the chronic morphine-treated group (Fig. 1A-B). In the 
amygdala, the OTR binding was increased both following chronic morphine administration 
and after 7-day morphine withdrawal compared to control groups. Moreover, the OTR 
binding showed a significant 1.5-fold increase following the 7-day withdrawal period 
compared to the morphine administration group (Fig. 1A-B). 
We also assessed OT peptide levels in several brain regions. A significant ‘treatment’ effect 
(Fig. 1C; Table 1) was observed in the hypothalamus, with a significant decrease of OT 
levels in the morphine-treated groups compared to the control groups, while no changes were 
observed in the septum. OT content in the hippocampus and amygdala was below the 
detection level (data not shown). 
To assess the effect of chronic morphine treatment and withdrawal on HPA axis activity, we 
measured plasma corticosterone levels at the end of the chronic administration paradigm and 
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after a 7-day withdrawal period. Chronic morphine treatment increased plasma corticosterone 
levels, while levels were comparable to the control group following a 7-day morphine 
withdrawal period (Fig. 1D; Table 1).  
Effect of chronic morphine treatment and subsequent abstinence on physical and 
behavioral withdrawal symptoms 
Acute, 1-day withdrawal from chronic morphine treatment induced withdrawal jumping (40 ± 
13 vs 0 ± 0 jumps; p<0.001; n=13-18 per group) and increased fecal boli production (12 ± 1 
vs 3 ± 1; p<0.001; n=13-18 per group), compared to the saline control group. In contrast, no 
significant differences between the morphine- and saline-treated groups were observed in 
either jumping behavior (0 ± 0 vs 0 ± 0 jumps; p>0.05) or defecation (4 ± 1 vs 4 ± 1; p>0.05) 
following 7-day withdrawal. Chronic morphine administration induced a significant decrease 
in food and water consumption, associated with a reduction in body mass (Supplementary 
Fig. 1S; Table 1). The drug withdrawal period was characterized initially by an increase in 
body mass, as well as food and water intake. Water consumption and body weight normalized 
to levels similar to saline-treated animals at the end of the 7-day withdrawal period 
(Supplementary Fig. S1). Moreover, morphine treatment reduced basal horizontal activity 
from Day 3 to 7 of the administration paradigm (Supplementary Fig. S3A; Table 1). This 
reduction persisted following the 7-day withdrawal period (Supplementary Fig. S3A). No 
alteration of basal vertical activity was observed between saline- and morphine-treated mice 
(Supplementary Fig. S3B).   
Effect of carbetocin, an oxytocin analogue, on anxiety-like, depressive-like and 
sociability behaviors associated with 7-day morphine withdrawal 
We assessed anxiety-like behavior following the 7-day withdrawal from morphine using the 
elevated plus-maze. Seven-day withdrawal from morphine decreased the time spent in the 
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open arms and the percentage of open arm entries compared to the control group (Fig. 2A-B), 
indicating anxiety-like behavior in rodents.  Administration of CBT prior to the behavioral 
test increased the time spent in the open arms in morphine-withdrawn mice to levels similar 
to the control group (Fig. 2A). In addition, CBT increased the number of entries in the open 
arms (Fig. 2B). CBT treatment did not induce any changes in the time spent and number of 
entries in the open arms for the control group (Fig. 2A-B). 
The forced-swim test was used to assess depressive-like behavior following 7-day withdrawal 
from morphine. Withdrawal increased immobility time (Fig. 3A), and reduced the latency to 
the first episode of immobility (Fig. 3B). In addition, an increase in fecal boli production was 
observed (Fig. 3C), also indicative of depressive-like behavior (Craft et al, 2010). CBT 
reduced the time spent immobile during the forced-swim test, as well as the production of 
fecal boli, and increased the latency to the first immobility episode, in the morphine-
withdrawn group to levels similar to the control group (Fig. 3A-C). Saline-withdrawn mice 
administered with CBT showed no significant changes in immobility time, latency to first 
immobility and fecal boli production compared to controls (Fig. 3A-C). 
We also assessed mouse sociability using the three-chambered social approach test. 
Sociability was measured by the time the subject mouse spent in the “social chamber” 
containing a novel conspecific compared to the “empty chamber”. We found a reduction of 
sociability behavior in morphine-withdrawn mice compared to the saline-withdrawn group 
(Fig. 4A). Administration of CBT prior to the behavioral test increased the time spent by 
morphine-withdrawn mice in the chamber containing the novel mouse compared to the empty 
chamber (Fig. 4A), indicating a restoration of sociability behavior. CBT had no effect on 
sociability in control mice undergoing withdrawal from saline (Fig. 4A). 
Furthermore, we assessed the preference of the subject mouse for either the chamber with the 
former conspecific (“familiar chamber”) or the chamber with a second “novel” mouse 
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(“novel chamber”) as indicative of preference for social novelty. Two-way ANOVA revealed 
an effect of morphine treatment (Fig. 4B) while the interaction ‘treatment’ (morphine vs 
saline) and ‘CBT’ was close to significance (p=0.06).  
Effect of carbetocin on stress-induced reinstatement of morphine-seeking behavior 
The CPP reinstatement paradigm is commonly used to assess relapse to drug-seeking 
(Cordery et al, 2012; Redila and Chavkin, 2008). Morphine administration induced a place 
preference in the CPP paradigm with an increase in the time spent in the drug-paired 
compartment in the post-conditioning phase compared to the pre-conditioning phase. The 5-
day extinction period led to a significant decrease in the time spent in the drug-paired 
compartment (post-extinction phase vs post-conditioning phase) (Fig. 5B; Table 1). A forced-
swim stress induced reinstatement of the CPP in mice treated with saline, as shown by the 
increased time spent in the drug-paired compartment compared to the post-extinction phase 
(Fig. 5B). In contrast, mice pre-injected with CBT did not show this increase in preference 
for the morphine-paired compartment during the reinstatement phase, compared to the saline 
pre-treated group (Fig. 5B). Furthermore, no changes in plasma corticosterone levels were 
observed in the CBT-treated group (244.3 ± 30.0 ng/ml; n=14) compared to the saline control 
group (252.6 ± 16.7 ng/ml; n=12) following stress-induced reinstatement. 
A possible mechanism by which CBT modulates the emotional impairment associated with 7-
day morphine withdrawal and the stress-induced reinstatement of morphine CPP is by 
inducing reward. Thus, we assessed the rewarding or aversive properties of CBT (6.4 mg/kg; 
i.p.) using the CPP paradigm. CBT did not induce any conditioned place preference or 
aversion (Fig. 5C; Table 1) compared to the saline control group. 
 
Discussion 
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This study demonstrated the protective effect of the OT analogue, CBT, on anxiety-, 
depressive-like behaviors and sociability impairment associated with abstinence from opioid 
administration, as well as on drug relapse, in a mouse model. In addition, we observed 
alterations of the OT-ergic system in the brain, which are likely to contribute to the 
emotional impairment observed following a 7-day withdrawal period from morphine. 
Altogether these findings highlight a key role of the OT-ergic system in opioid addiction and 
relapse, suggesting this system as a novel target for the treatment of opioid addiction, and in 
particular for preventing relapse.  
We first established and characterized a mouse model of 7-day opioid abstinence which 
mimics the physical and emotional symptoms usually displayed by human opioid-withdrawn 
addicts (Jaffe, 1990; Martin et al, 1969). While acute physical withdrawal symptoms (i.e., 
withdrawal jumping, defecation, as well as changes in body mass) had disappeared after 7 
days of morphine abstinence, anxiety-, depressive-like behaviors were increased and 
sociability reduced, highlighting the translational value of this model and the direct 
relationship between opioid abstinence and the emergence of negative emotional state. 
Consistent with the work of (Zhou et al, 2006), while chronic morphine treatment enhanced 
the HPA axis activity, corticosterone levels returned to levels similar to those of controls after 
the 7-day withdrawal period, demonstrating a normalization of the HPA axis. We also 
demonstrated that chronic morphine administration and/or withdrawal was associated with 
alterations of the central OT-ergic system. We not only observed reduced levels of OT in the 
hypothalamus, the main site of OT synthesis in the brain, but also an increase in OTR binding 
in several regions where OT-producing neurons project (i.e., olfactory nuclei, piriform cortex, 
septum and amygdala) (Gimpl et al, 2001), suggestive of compensatory mechanisms to the 
reduced OT-ergic tone. Similar neuroadaptive changes in the oxytocinergic system were 
previously observed following an acute morphine tolerance paradigm (Sarnyai et al, 
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1988). Using a specific oxytocin receptor antagonist, Sarnyai et al, showed a key role of 
oxytocin receptors located in the posterior olfactory nucleus and central nucleus of the 
amygdala in acute tolerance to morphine. Our findings are also consistent with decreased 
OT contents in several brain regions following chronic morphine administration in rodents 
(Kovacs et al, 1987; You et al, 2000). In addition, our data demonstrate that these OT-ergic 
alterations not only persisted following the 7-day withdrawal period, but was further 
heightened with respect to OTR binding in the septum and amygdala, regions playing a key 
role in the regulation of stress and emotions (Phelps and LeDoux, 2005; Singewald et al, 
2011). This is in line with a previous study in a rodent model of social deficit in 
schizophrenia showing that while hypothalamic oxytocin mRNA levels were 
significantly decreased, oxytocin receptor binding was increased in the central nucleus 
of the amygdala (Lee et al, 2005). The fact that both the septum and amygdala have been 
implicated in the stress-regulating and social-enhancing properties of OT (Domes et al, 2007; 
Lukas et al, 2013) is further suggestive of  the OT-ergic system involvement in the negative 
emotional consequences of opioid withdrawal.  
In this translational model, we demonstrated that CBT reversed not only anxiety- and 
depressive-like behaviors, but also restored sociability in morphine-withdrawn mice to levels 
similar to the control saline-withdrawn groups. Importantly, CBT did not affect the anxiety 
level, depressive-like state or sociability in control saline-withdrawn mice. In addition, 
locomotor activity showed no difference after CBT administration in naïve mice compared to 
saline-treated mice (data not shown). These findings strongly support the specificity of the 
anxiolytic, antidepressant and pro-social effects induced by a relatively low dose of CBT to 
counteract the negative consequences of withdrawal. While CBT shows a high affinity for 
both OTR and vasopressin V1 receptors in rat myometrial homogenates (Engstrom et 
al, 1998), its effects are likely mediated by OTR, since a recent study demonstrated 
15 
 
antidepressant-like effects of the same dose via specific activation of the central OTR 
and not vasopressin V1A receptors (Chaviaras et al, 2010). Addressing emotional 
impairment associated with opioid abstinence is essential given the high comorbidity with 
depression along with the ambiguous efficacy of classic antidepressant treatment in this 
patient population (Nunes et al, 2004). In addition, the pro-social effect of CBT in morphine-
withdrawn mice is consistent with previous reports demonstrating the key role of OT in the 
positive modulation of social behaviors (Lukas et al, 2011; Neumann et al, 2012). This is of 
particular interest as it represents the first attempt to modulate sociability deficits associated 
with opioid addiction. Although understudied, prolonged use of addictive substances often 
results in disintegration of the social lives due to social isolation and poor decision making at 
the expense of compulsive pre-occupation with the drug and its related cues (Dawe et al, 
2009; Volkow et al, 2011). Considering the therapeutic success of social support programs, 
as well as the benefits of social rehabilitation and reintegration in keeping former addicts in a 
drug-free state (McGregor et al, 2012), the use of OT-ergic compounds in combination with 
psycho-social support may prove to be effective in preventing relapse by promoting positive 
social behavior. The pro-social effect of OT-ergic pharmacotherapy is being assessed in 
clinical trials for the treatment of social deficit in autistic spectrum disorders and 
schizophrenia (Carter, 2007; Heinrichs and Gaab, 2007). Interestingly, a decrease in the 
hypothalamic OT mRNA expression, as well as an increase in OTR binding in the amygdala, 
was observed in a mouse model of schizophrenia displaying social behavior deficits (Lee et 
al, 2005). Overall, these findings further support a causal relationship between the alterations 
observed within the OT peptidergic system and impaired social behavior.  
In addition, CBT prevented stress-induced reinstatement of morphine CPP. Our findings are 
consistent with (Qi et al, 2009) who showed a beneficial effect of OT on attenuating 
reinstatement of methamphetamine CPP induced by restraint stress. This modulatory effect of 
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CBT may involve regulation of drug reward as shown by the ability of OT to inhibit both 
methamphetamine- and cocaine-induced increase in dopamine utilization in the striatum 
(Kovacs et al, 1990; Qi et al, 2008). However, in our study, CBT, at 6.4 mg/kg (i.p.), was 
neither rewarding nor aversive in the CPP paradigm. An alternative mechanism underlying 
the effects of CBT may involve modulation of the HPA axis (Windle et al, 2004). However, 
in our study, carbetocin did not induce any differences in plasma corticosterone levels 
following stress-induced reinstatement. While these results suggest that the peripheral 
part of the HPA axis is not altered by CBT, its potential action via extra-hypothalamic 
brain stress systems (e.g., corticotropin-releasing factor, CRF) cannot be ruled out. In 
particular, the CRF system in the amygdala has been shown to play a key role in the 
aversive/emotional consequences of drug withdrawal (Erb, 2010; Heinrichs et al, 1995; 
Koob, 2009; Stinus et al, 2005) and stress-induced reinstatement of drug-seeking (Erb et 
al, 2001; Erb et al, 1998; Koob, 2009; Wang et al, 2006). 
Taken together, our findings showed that the OT analogue CBT can prevent the negative 
emotional impairment, encompassing anxiety-, depressive-like behavior, reduction of 
sociability, as well as reinstatement of drug-seeking in a translational mouse model of opioid 
withdrawal. Future studies using opiate self-administration paradigms could be used to 
validate further these findings. Overall, our results highlight the alterations of the OT-
ergic system as one of the underlying mechanisms of emotional impairment associated with 
long-term abstinence in opioid addicts. Thus, OT-ergic pharmacotherapy might constitute a 
novel potential target to assist opioid addicts with relapse prevention by treating mood 
disorders and social impairment associated with drug-withdrawal. The effects of chronic OT-
ergic pharmacotherapy on the alleviation of negative emotional symptoms remain to be 
characterized to validate its progress towards clinical development. 
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Legends for Table and Figures 
Table 1. Relevant effects for biochemical and behavioral data (two-way ANOVA)  
Figure 1. Oxytocin receptor (OTR) binding, oxytocin (OT) peptide levels in the brain 
and plasma corticosterone levels following 7-day morphine abstinence. Male C57BL/6J 
mice were treated for seven days with either saline or chronic morphine followed by a 
withdrawal period of 7 days. (A) Representative autoradiograms of 50 pM [125I]-ornithine 
vasotocin analogue binding to OTRs in coronal brain sections at the level of the olfactory 
nuclei (row 1), striatum (row 2), septum (row 3) and thalamus (row 4). Binding levels are 
represented using a pseudo-colour interpretation of black and white film images in fmol/mg 
of tissue equivalent. (B) Quantitative OTR binding levels in brain regions where OTRs are 
expressed. (C) OT peptide levels in the septum and hypothalamus. (D) Corticosterone levels 
in plasma. Data are expressed as mean ± SEM (n=5-7 per group). *p<0.05; **p<0.01; 
***p<0.001 (two-way ANOVA followed by Holm-Sidak post-hoc test when appropriate). 
Abbreviations: Acb, nucleus accumbens; Amy, amygdala; AOL, anterior olfactory nucleus-
lateral; AOM, anterior olfactory nucleus-medial; AOV, anterior olfactory nucleus-ventral; 
CgCx, cingulate cortex; CPu, caudate putamen; Hip, hippocampus; Hyp, hypothalamus; LS, 
lateral septum; MS, medial septum;  Pir, piriform cortex; PV Th, paraventricular nucleus of 
thalamus; Th, thalamus; Tu, olfactory tubercle; VDB, vertical limb of diagonal band of 
Broca.  
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Figure 2. Anxiety-like behavior induced by 7-day morphine withdrawal is reversed by 
the oxytocin analogue carbetocin (CBT). (A) Time spent in the open arms and (B) 
percentage of entries in the open arms of the elevated plus-maze. Seven-day withdrawal from 
chronic morphine treatment induced an increase in anxiety-like behavior which was reversed 
by CBT (6.4 mg/kg, i.p.). Data are expressed as mean ± SEM (n=6-10 per group). **p<0.01 
(two-way ANOVA followed by Holm-Sidak post-hoc test when significance was reached). 
Abbreviations: Sal, saline; Mor, morphine. 
Figure 3. Depressive-like behavior induced by 7-day morphine withdrawal is prevented 
by the oxytocin analogue carbetocin (CBT). (A) Immobility time, (B) latency to the first 
episode of immobility, and (C) number of fecal boli were measured during the 5-min forced-
swim test. In 7-day morphine-withdrawn animals, immobility time and production of fecal 
boli were increased while the latency to the first episode of immobility was decreased in the 
forced-swim test, indicative of enhanced depressive-like behaviors. Administration of CBT 
(6.4 mg/kg, i.p.) reversed these effects of 7-day morphine withdrawal to levels comparable to 
the saline control group. Data are expressed as mean ± SEM (n=6-10 per group). *p<0.05; 
**p<0.01, ***p<0.001 (two-way ANOVA followed by Holm-Sidak post-hoc test when 
significance was reached). Abbreviations: Sal, saline; Mor, morphine. 
Figure 4. Carbetocin (CBT) restores sociability behavior following 7-day morphine 
withdrawal using the three-chambered social approach test. (A) Sociability defined by 
the ratio of the time spent in the chamber containing the novel conspecific (“social chamber”) 
vs the empty chamber during the 10-min “sociability” phase. Mice were then tested for (B) 
preference for social novelty as defined by the ratio of the time spent in the chamber 
containing a novel unfamiliar mouse (“novelty chamber”) vs the chamber containing the 
former conspecific (“familiar chamber”) during the 10-min “preference for social novelty” 
phase. While mice withdrawn from chronic morphine treatment displayed a reduction in 
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sociability compared to the saline-withdrawn group, CBT (6.4mg/kg, i.p.) restored 
sociability. Preference for social novelty was decreased in the chronic morphine-treated 
groups. Data are expressed as mean ± SEM (n=6-10 per group). *p<0.05, **p<0.01; 
***p<0.001 (two-way ANOVA followed by Holm-Sidak post-hoc test when significance 
was reached). Abbreviations: Sal, saline; Mor, morphine. 
Figure. 5. Effect of carbetocin (CBT) on stress-induced reinstatement of morphine-
seeking behavior and conditioned place preference (CPP). (A) Experimental protocol with 
the different phases of the CPP paradigm. Twenty-six mice underwent the following 
protocol: Habituation phase; Pre-conditioning (Pre-Cond) phase: assessment of spontaneous 
place preference; Conditioning phase: 4 consecutive days with saline injection (10 ml/kg, s.c., 
first half of light period) in the preferred compartment and administration of morphine (10 
mg/kg, s.c. 4 hours after the saline injection) in the least-preferred compartment; Post-
conditioning (Post-Cond) session: assessment of conditioning with no injection; Extinction 
phase: 5 consecutive days with saline injection (10 ml/kg, s.c. first half of light period) and 
then, administration of saline (10 ml/kg, s.c. 4 hours after the first daily injection) in the drug-
paired compartment; Post-extinction (Post-Ext) test: assessment of extinguished behavior - no 
injection; For the reinstatement test, mice were then subdivided into two experimental groups 
to receive either saline (4 ml/kg, i.p.; n=14) or CBT (6.4 mg/kg, i.p.; n=12), followed by 
exposure to a forced-swim stress 5 minutes later (23 ± 1oC; 6 min). Mice were then tested for 
reinstatement of morphine-seeking behavior during a 20-min session. (B) Time spent in the 
morphine-paired compartment for each phase of the CPP paradigm (analysis of the last 15 
min of the 20-min session). Data are expressed as mean ± SEM (n=12-14 mice per group); 
*p<0.05; ***p<0.001. (C) Time spent in the CBT- or saline-paired compartment (analysis of 
the last 15 minutes of the 20-min session) during the pre-conditioning (Pre-Cond) and post-
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conditioning (Post-Cond) phases of the CPP paradigm.  Data are expressed as mean ± SEM 
(n=6 mice per group).  
 
O
TR
 s
pe
ci
fic
 b
in
di
ng
  
(fm
ol
/m
g 
tis
su
e)
 
4.176 
2.340 
0.960 
0.072 
O
TR
 b
in
di
ng
  
(fm
ol
/m
g 
tis
su
e)
 
Saline Morphine 
Saline 
Withdrawal 
Morphine 
Withdrawal A 
B 
Non-Specific 
Binding 
Brain Region 
Brain Region 
O
T 
pe
pt
id
e 
le
ve
ls
 
(p
g/
m
g 
tis
su
e)
 
C 
Pl
as
m
a 
co
rt
ic
os
te
ro
ne
 
le
ve
ls
 (n
g/
m
l) 
# 
D 
Bregma  
2.46mm 
Bregma  
0.86mm 
Bregma  
0.14mm 
Bregma  
-2.06mm 
A 
B 
A 
B 
C 
A 
B 
A 
B 
C 
Days 
Ti
m
e 
sp
en
t i
n 
dr
ug
-p
ai
re
d 
co
m
pa
rt
m
en
t (
se
c)
 
Ti
m
e 
sp
en
t i
n 
dr
ug
-p
ai
re
d 
co
m
pa
rt
m
en
t (
se
c)
 
Treatment effect Interaction effect
Overall effects for Figure 1
OTR autoradiography Factor 'treatment' Factor 'treatment' x '7-day withdrawal'
AOM F[1,16] = 0.323; p=0.32 F[1,16] = 0.83; p=0.38
AOV F[1,16] = 11.40; p<0.01 F[1,16] = 1.20; p=0.29
AOL F[1,16] = 8.14; p<0.05 F[1,16] = 0.49; p=0.49
CgCx F[1,16] = 0.02; p=0.89 F[1,16] = 0.17; p=0.69
Pir F[1,16] = 19.88; p<0.001 F[1,16] = 2.80; p=0.11
Tu F[1,16] = 1.88; p=0.19 F[1,16] = 0.56; p=0.46
Acb F[1,16] = 3.34; p=0.09 F[1,16] = 1.55; p=0.23
CPu F[1,16] = 0.94; p=0.35 F[1,16] = 0.21; p=0.65
MS F[1,16] = 10.06; p<0.01 F[1,16] = 1.48; p=0.24
VDB F[1,16] = 6.40; p<0.05 F[1,16] = 0.76; p=0.40
LS F[1,16] = 13.72; p<0.01 F[1,16] = 4.46; p=0.05
Hip F[1,16] = 0.01; p=0.93 F[1,16] = 0.31; p=0.59
Th F[1,16] = 0.04; p=0.84 F[1,16] = 3.10; p=0.10
Amy F[1,16] = 64.55; p<0.001 F[1,16] = 4.98; p<0.05
OT peptide levels Factor 'treatment' Factor 'treatment' x '7-day withdrawal'
Septum F[1,22] = 0.32; p=0.58 F[1,22] = 0.25; p=0.63
Hyp F[1,22] = 15.81; p<0.001 F[1,22] = 0.29; p=0.60
Corticosterone F[1,43] = 10.81; p<0.01 F[1,43] =21.34; p<0.001
Overall effects for Figure 2
Anxiety-like Behavior Factor 'treatment' Factor 'treatment' x 'CBT'
Open-arm time F[1,29] = 6.80; p<0.05 F[1,29] = 5.67; p<0.05
Open-arm entries (%) F[1,29] = 0.78; p=0.39 F[1,29] = 2.36; p=0.14
Overall effects for Figure 3
Depressive-like Behavior Factor 'treatment' Factor 'treatment' x 'CBT'
Immobility time F[1,28] = 24.67; p<0.001 F[1,28] = 19.11; p<0.001
Latency to first immobility F[1,28] = 17.36; p<0.001 F[1,28] = 5.37; p<0.05
Faecal Boli F[1,28] = 17.30; p<0.001 F[1,28] = 8.66; p<0.01
Overall effects for Figure 4
Social Approach Behavior Factor 'treatment' Factor 'treatment' x 'CBT'
Sociability F[1,25] = 0.003; p=0.95 F[1,25] = 10.19; p<0.01
Preference for social novelty F[1,25] = 11.72; p<0.01 F[1,25] = 4.04; p=0.06
Overall effects for Figure 5
Conditioned-place preference Factor 'experiment' Factor 'experiment' x 'CPP phase'
Morphine-induced reinstatement F[1,96] = 10.52; p<0.01 F[3,96] = 3.26; p<0.05
Factor 'CBT' Factor 'CBT' x 'CPP phase'
CBT-induced CPP F[1,10] = 0.05; p=0.83 F[1,10] < 0.001; p=1.00
Overall effects for Supplementary Figure 1
Physical dependence Factor 'treatment' Factor 'treatment' x 'days'
Weight F[1,34] = 17.17; p=0.22 F[14,476] =23.70; p<0.001
Food consumnption F[1,34] = 2.32; p=0.14 F[14,466] =107.04; p<0.001
Water consumption F[1,34] <0.001; p=9.76 F[14,446] =23.85; p<0.001
Overall effects for Supplementary Figure 2
Depressive-like Behaviour Factor 'treatment' Factor 'treatment' x 'CBT'
Immobility time F[1,36] = 15.63; p<0.001 F[3,36] = 4.88; p<0.01
Latency to first immobility F[1,36] = 25.58; p<0.001 F[3,36] = 3.86; p<0.05
Faecal Boli F[1,36] = 9.38; p<0.01 F[1,28] = 3.69; p<0.01
Overall effects for Supplementary Figure 4
Effect of withrdrawal on basal locomotion Factor 'treatment' Factor 'treatment' x 'days'
Horizontal activity F[1,16] = 27.77; p<0.001 F[7,112] = 5.89; p<0.001
Vertical activity F[1,16] = 0.40; p=0.39 F[7,112] = 0.39; p=0.91
